Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic rivaroxaban 20 mg vs Xarelto under fed conditions in healthy Thai volunteers
TCTR20230222007Phase 1Unknown
- Sponsor
- International Bio Service
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), coronary arteriosclerosis and 1 more (2 arms), sponsored by International Bio Service. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)coronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on TCTR20230222007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230222007.